Hematologic and hemostatic changes induced by different columns during LDL apheresis

Journal of Clinical Apheresis

Volumn 25, Issue 5, 2010, Pages 294-300

  Hovland, Anders ^a,b   Hardersen, Randolf ^a   Nielsen, Erik Waage ^a,c   Mollnes, Tom Eirik ^a,b   Lappegård, Knut Tore ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORD UNIVERSITY   (Norway)

Author keywords

apheresis; familial hypercholesterolemia; hematology; hemostasis; homocysteine; LDL cholesterol

Indexed keywords

FIBRINOGEN; HEMOGLOBIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; PEPTIDE HYDROLASE;

ADULT; APHERESIS; ARTICLE; CASE REPORT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; LEUKOCYTE; MALE; RISK FACTOR; THROMBOCYTE; BLOOD; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED;

ADULT; ANTITHROMBIN III; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; FEMALE; FIBRINOGEN; HEMOSTASIS; HOMOCYSTEINE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 79151481191     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20256     Document Type: Article

References (42)

1. Thompson GR,. LDL apheresis. Atherosclerosis 2003; 167: 1-13. (Pubitemid 36258395)
2. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142: 105-112.
3. Neil HA, Huxley RR, Hawkins MM, Durrington PN, Betteridge DJ, Humphries SE,. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 2003; 170: 73-78. (Pubitemid 37083565)
4. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T,. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL- Apheresis Study Group. Am J Cardiol 1998; 82: 1489-1495. (Pubitemid 29006472)
5. Bosch T, Wendler T,. State of the art of low-density lipoprotein apheresis in the year 2003. Ther Apher Dial 2004; 8: 76-79. (Pubitemid 38796935)
6. Thompsen J, Thompson PD,. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006; 189: 31-38. (Pubitemid 44444914)
7. Kroon AA, Aengevaeren WR, van der WT, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF,. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-1835. (Pubitemid 26154034)
8. Gordon BR, Kelsey SF, Dau PC, Gotto AM, Jr., Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ,. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group Am J Cardiol 1998; 81: 407-411. (Pubitemid 28099529)
9. Bosch T,. Therapeutic apheresis-state of the art in the year 2005. Ther Apher Dial 2005; 9: 459-468. (Pubitemid 43923973)
10. Bambauer R,. Low-density lipoprotein apheresis: clinical results with different methods. Artif Organs 2002; 26: 133-139. (Pubitemid 34225209)
11. Thompson GR,. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-255.
12. Hovland A, Hardersen R, Sexton J, Mollnes TE, Lappegard KT,. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 2009; 24: 247-253.
13. Schechner V, Shapira I, Berliner S, Comaneshter D, Hershcovici T, Orlin J, Zeltser D, Rozenblat M, Lachmi K, Hirsch M, Beigel Y,. Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Eur J Clin Invest 2003; 33: 955-961. (Pubitemid 37421593)
14. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, Seidel D,. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004; 175: 145-150. (Pubitemid 38746921)
15. Jaeger BR, Goehring P, Schirmer J, Uhrig S, Lohse P, Kreuzer E, Reichart B, Seidel D,. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach. Ther Apher 2001; 5: 252-259. (Pubitemid 33062672)
16. Bosch T, Wendler T, Jaeger BR, Samtleben W,. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther Apher 2001; 5: 372-376. (Pubitemid 34033335)
17. Sprengers ED, Kluft C,. Plasminogen activator inhibitors. Blood 1987; 69: 381-387. (Pubitemid 17022002)
18. Hamsten A, de FU, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B,. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9. (Pubitemid 17083665)
19. Nilsson JB, Boman K, Jansson JH, Nilsson T, Naslund U,. The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase. J Thromb Thrombolysis 2008; 26: 188-195.
20. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG,. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003; 27: 1116-1122. (Pubitemid 38037567)
21. Bosch T,. Practical aspects of direct adsorption of lipoproteins from whole blood by DALI LDL-apheresis. Transfus Apher Sci 2004; 31: 83-88. (Pubitemid 40292132)
22. Kobayashi A, Nakatani M, Furuyoshi S, Tani N,. In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein-hemoperfusion. Ther Apher 2002; 6: 365-371. (Pubitemid 35192327)
23. Kojima S, Shida M, Yokoyama H,. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003; 7: 431-434. (Pubitemid 37082032)
24. Klingel R, Fassbender T, Fassbender C, Gohlen B,. From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. Ther Apher Dial 2003; 7: 350-358. (Pubitemid 36859526)
25. Hershcovici T, Schechner V, Orlin J, Harell D, Beigel Y,. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J Clin Apher 2004; 19: 90-97. (Pubitemid 39006614)
26. Kopprasch S, Julius U, Gromeier S, Kuhne H, Graessler J,. Distinct effects of LDL apheresis by hemoperfusion (DALI) and heparin-induced extracorporeal precipitation (HELP) on leukocyte respiratory burst activity of patients with familial hypercholesterolemia. J Clin Apher 2000; 15: 249-255.
27. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di MC, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F,. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
28. Bramlage CP, Armstrong VW, Zapf A, Bramlage P, Mueller GA, Koziolek MJ,. Low-Density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther Apher Dial 2010; 14: 136-142.
29. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS,. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40: 27-33. (Pubitemid 34701373)
30. Turner SJ, Ketch TR, Gandhi SK, Sane DC,. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 2008; 155: 806-816.
31. Loimaala A, Rontu R, Vuori I, Mercuri M, Lehtimaki T, Nenonen A, Bond MG,. Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middle-aged men. Atherosclerosis 2006; 188: 363-369. (Pubitemid 44313926)
32. Fibrinogen studies collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-1809.
33. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T,. LDL-apheresis reduces P-Selectin, CRP and fibrinogen-possible important implications for improving atherosclerosis. Ther Apher Dial 2006; 10: 219-223. (Pubitemid 43979290)
34. Dihazi H, Koziolek MJ, Söllner T, Kahler E, Klingel R, Neuhoff R, Strutz F, Mueller GA,. Protein adsorption during ldl-apheresis: proteomic analysis. Nephrol Dial Transplan 2008; 23: 2925-2935.
35. Ulrich-Mockel NV, Riehle M, Vollert J, Heller G, Jr., Stork T, Riess H, Muller C, Frei U, Mockel M,. Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. Biomarkers 2009; 14: 311-316.
36. Maher VM, Kitano Y, Neuwirth C, Davies GJ, Maseri A, Thompson GR, Andreotti F,. Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. J Thromb Thrombolysis 2009; 28: 166-172.
37. Bosch T, Heinemann O, Duhr C, Wendler T, Keller C, Fink E, Kirschner T, Klebert S, Samtleben W,. Effect of low-dose citrate anticoagulation on the clinical safety and efficacy of direct adsorption of lipoproteins (DALI apheresis) in hypercholesterolemic patients: a prospective controlled clinical trial. Artif Organs 2000; 24: 790-796.
38. Vaughan DE,. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883. (Pubitemid 41716575)
39. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C,. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
40. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K,. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588.
41. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr,. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577.
42. Mager A, Orvin K, Koren-Morag N, Lev IE, Assali A, Kornowski R, Shohat M, Battler A, Hasdai D,. Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol 2009; 104: 745-749.